Although GHRH-antagonists have not yet been introduced into the clinical practice, the potential importance of GHRH-R both as a probable molecular target of therapy and—based on our present findings—as a predictor for survival in locally advanced rectal cancer is highly plausible. The gene discussed is GHRH; the disease is rectal cancer.